ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
Dow Jones
43,297.03
0.91%
US Dollar vs MXN
20.1663
0.00%
Brent Oil
73.425
0.19%
Bitcoin
98,452.86
-0.85%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. IDEAYA Biosciences Inc (IDYA)

  7. IDEAYA Biosciences Inc (IDYA) Noticias

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IDYA
FechaHoraFuenteTítuloSímboloCompañía
20/12/202415:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
17/12/202405:00PR Newswire (US)IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
16/12/202405:00PR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung CancersNASDAQ:IDYAIDEAYA Biosciences Inc
11/12/202405:00PR Newswire (US)IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
10/12/202405:00PR Newswire (US)IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
09/12/202405:00PR Newswire (US)IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 InhibitorNASDAQ:IDYAIDEAYA Biosciences Inc
06/12/202405:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
02/12/202405:00PR Newswire (US)IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
18/11/202405:00PR Newswire (US)IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial OfficerNASDAQ:IDYAIDEAYA Biosciences Inc
12/11/202405:00PR Newswire (US)IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202409:40Business WireBiocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der...NASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202409:40Business WireBiocytogen annonce la nomination par IDEAYA du candidat IDE034, un ADC bispécifique Topo-I-Payload B7H3/PTK7, ainsi que la levée d’une optionNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202405:00Business WireBiocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option ExerciseNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/202405:00PR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with BiocytogenNASDAQ:IDYAIDEAYA Biosciences Inc
04/11/202407:30PR Newswire (US)/C O R R E C T I O N -- IDEAYA Biosciences, Inc./NASDAQ:IDYAIDEAYA Biosciences Inc
04/11/202405:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
04/11/202405:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
28/10/202405:00PR Newswire (US)IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
25/10/202405:00PR Newswire (US)IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024NASDAQ:IDYAIDEAYA Biosciences Inc
04/10/202405:00PR Newswire (US)IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR SymposiumNASDAQ:IDYAIDEAYA Biosciences Inc
27/09/202415:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
23/09/202405:00PR Newswire (US)IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
22/09/202408:00PR Newswire (US)IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
18/09/202405:00PR Newswire (US)IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General CounselNASDAQ:IDYAIDEAYA Biosciences Inc
26/08/202416:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
26/08/202405:00PR Newswire (US)IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202416:08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202415:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
06/08/202405:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
31/07/202418:56Business Wire百奧賽圖宣布與IDEAYA Biosciences就具有同類首創潛力的B7H3/PTK7拓撲異構酶抑制劑有效負載雙特異性ADC專案達成選擇權和授權合約NASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA

Su Consulta Reciente

NYSE
BAC
Bank of America
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
PM
XAUUSD
Gold vs US Dollar
AMEX
SPY
SPDR S&P 500
USI
USTECH100
US Tech 100
NYSE
NKE
Nike
CCOM
OILBRENT
Brent Oil
FX
EURMXN
Euro vs MXN
COIN
ADAUSD
Cardano
SPI
SP500
S&P 500
COIN
SOLUSD
Solana
NYSE
JPM
JP Morgan Chase
AMEX
XLV
Health Care Select Sector
NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados